Thursday, March 26th, 2026
Yoga
7:00 AM - 8:00 AM
Continental Breakfast
7:00 AM - 8:00 AM
Robin Weber Symposium: Updates in Psoriasis Management
GS210 8:00 AM - 9:00 AM
Speaker: Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, FSDNP
This session will provide a comprehensive overview of the management of psoriasis using an interactive, and fun case-based format. We will review the pathogenesis and clinical presentation of the many variants of psoriasis. We will identify and explain the immune-based targets that provide therapeutic targets, focusing on the newest psoriasis treatments. Finally, we will discuss patient education to enhance understanding and adherence to therapy and improved quality of life.
Learning Objectives:
The learner will be to identify 3 new therapeutic targetsfort the management of psoriasis.
ANCC CE 1.0 | Pharmacotherapeutics 0.5 - 30 Minutes
Speaker: Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, FSDNP
This session will provide a comprehensive overview of the management of psoriasis using an interactive, and fun case-based format. We will review the pathogenesis and clinical presentation of the many variants of psoriasis. We will identify and explain the immune-based targets that provide therapeutic targets, focusing on the newest psoriasis treatments. Finally, we will discuss patient education to enhance understanding and adherence to therapy and improved quality of life.
Learning Objectives:
The learner will be to identify 3 new therapeutic targetsfort the management of psoriasis.
ANCC CE 1.0 | Pharmacotherapeutics 0.5 - 30 Minutes
Acne Management
GS220 9:00 AM - 10:00 AM
Speaker: Carla Torres-Zegarra, MD
From Breakouts to Balance: Practical Acne Management provides a clear, evidence-based approach to diagnosing and treating acne across severity levels. Designed for clinical practice, this session equips healthcare professionals with practical treatment algorithms, tips for medication selection, and effective patient counseling strategies to improve adherence, manage side effects, and achieve better skin outcomes.
Learning Objectives:
Identify the key pathogenic factors of acne and use them to guide individualized, evidence-based treatment selection. Apply a stepwise, severity-based approacht o acne management using topical and systemic therapies. Implement effective patient counseling strategies to improve adherence, manage side effects,and set realistic expectations.
ANCC CE 1.0
Speaker: Carla Torres-Zegarra, MD
From Breakouts to Balance: Practical Acne Management provides a clear, evidence-based approach to diagnosing and treating acne across severity levels. Designed for clinical practice, this session equips healthcare professionals with practical treatment algorithms, tips for medication selection, and effective patient counseling strategies to improve adherence, manage side effects, and achieve better skin outcomes.
Learning Objectives:
Identify the key pathogenic factors of acne and use them to guide individualized, evidence-based treatment selection. Apply a stepwise, severity-based approacht o acne management using topical and systemic therapies. Implement effective patient counseling strategies to improve adherence, manage side effects,and set realistic expectations.
ANCC CE 1.0
Exhibits & Poster Viewing
10:00 AM - 11:30 AM
The Sun Bus
10:30 AM - 11:00 AM
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients With Certain Skin Diseases Driven in Part by Type 2 Inflammation
Lunch Symposium 11:45 AM - 1:00 PM
Speaker: Leigh Ann Pansch, MSN, FNP-BC, DCNP
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with skin diseases driven in part by Type 2 inflammation.
Supported by Regeneron and Sanofi
Speaker: Leigh Ann Pansch, MSN, FNP-BC, DCNP
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with skin diseases driven in part by Type 2 inflammation.
Supported by Regeneron and Sanofi
Poster Symposium
GS240 1:00 PM - 1:30 PM
Speaker: Michelle Clarahan, BSN, RN, DNC, CPN and Mitzi Paulsen, BSN, RN
Learning Objectives:
Identify the benefit of providing an infant scale tool to families who have an infant taking oral therapy for treatment of infantile hemangiomas. Describe how to decrease sharp injuries in a dermatology surgical area.
ANCC CE 0.5 | Pharmacotherapeutics 0.1
Speaker: Michelle Clarahan, BSN, RN, DNC, CPN and Mitzi Paulsen, BSN, RN
Learning Objectives:
Identify the benefit of providing an infant scale tool to families who have an infant taking oral therapy for treatment of infantile hemangiomas. Describe how to decrease sharp injuries in a dermatology surgical area.
ANCC CE 0.5 | Pharmacotherapeutics 0.1
Empowering Hairdressers to Identify Scalp Skin Abnormalities: A Missed Opportunity in Community Dermatologic Surveillance
GS242 1:30 PM - 2:00 PM
Speaker: James Caleb Runyon, MSN, NP-C
This presentation focuses on introducing the viewers to the following: a problem which is that many skin cancers go unnoticed or get late diagnoses, hairdressers have a unique opportunity in identifying these lesions by their up close & personal roles in client care.
Learning Objectives:
Describe the importance of community & public health education as it pertains to early detection of skin cancer.
ANCC CE 1.0
Speaker: James Caleb Runyon, MSN, NP-C
This presentation focuses on introducing the viewers to the following: a problem which is that many skin cancers go unnoticed or get late diagnoses, hairdressers have a unique opportunity in identifying these lesions by their up close & personal roles in client care.
Learning Objectives:
Describe the importance of community & public health education as it pertains to early detection of skin cancer.
ANCC CE 1.0
Exhibits & Poster Viewing
2:00 PM - 3:00 PM
The Sun Bus
2:25 PM - 2:45 PM
The Complexities of Treating Severe Alopecia Areata in Adolescents and Adults with Common (and Uncommon) Comorbidities
GS250 3:00 PM - 4:00 PM
Speakers: Keischa Cash, DNP, APRN, DCNP, FNP-BC and Patricia Delgado, DNP, AGPCNP, DCNP
Educational grant provided by Pfizer
This session will help to improve the knowledge and competence of dermatology advanced practice providers and nurses regarding the assessment of disease severity, treatment, overall care management, and impact on patient quality of life related to atopic dermatitis (AD) and alopecia areata (AA) among adults and adolescents.
Learning Objectives:
Determine the frequency of inadequate disease control among patients with atopic dermatitis (AD) treated with biologic therapy. Analyze common JAK inhibitor dosing schedules among patients with AD.
ANCC CE 1.0 | Pharmacotherapeutics 0.33
Speakers: Keischa Cash, DNP, APRN, DCNP, FNP-BC and Patricia Delgado, DNP, AGPCNP, DCNP
Educational grant provided by Pfizer
This session will help to improve the knowledge and competence of dermatology advanced practice providers and nurses regarding the assessment of disease severity, treatment, overall care management, and impact on patient quality of life related to atopic dermatitis (AD) and alopecia areata (AA) among adults and adolescents.
Learning Objectives:
Determine the frequency of inadequate disease control among patients with atopic dermatitis (AD) treated with biologic therapy. Analyze common JAK inhibitor dosing schedules among patients with AD.
ANCC CE 1.0 | Pharmacotherapeutics 0.33
Sound Bath Session
4:00 PM - 4:30 PM
Aesthetic Reconstruction After Mohs Surgery
GS260 4:00 PM - 5:00 PM
Speaker: David Archibald MD, PC
Facial reconstruction following Mohs surgery has traditionally focused on simply closing the resulting defect, prioritizing functional closure over aesthetic outcomes. However, a significant paradigm shift is emerging within our field, moving beyond mere "patching the hole" toward an integrated aesthetic approach. We will review how many of the same approaches used in cosmetic surgery should be employed during reconstructive surgery, allowing us to restore function but also the emotional well-being of our patients.
Learning Objectives:
Identify the paradigm shift on how we look at facial reconstruction after Mohs
ANCC CE 1.0
Speaker: David Archibald MD, PC
Facial reconstruction following Mohs surgery has traditionally focused on simply closing the resulting defect, prioritizing functional closure over aesthetic outcomes. However, a significant paradigm shift is emerging within our field, moving beyond mere "patching the hole" toward an integrated aesthetic approach. We will review how many of the same approaches used in cosmetic surgery should be employed during reconstructive surgery, allowing us to restore function but also the emotional well-being of our patients.
Learning Objectives:
Identify the paradigm shift on how we look at facial reconstruction after Mohs
ANCC CE 1.0
Advanced Practitioner Psoriasis Recognition Program (APReP)
5:30pm - 8:00pm
Speakers: Tomas Chao, PA-C - Atlanta North Dermatology Lakshi Aldredge, ANP, MSN, ANP-BC, DCNP - VA Hospital
Credit Designation: The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity is supported by independent educational grants from Johnson and Johnson Innovative Medicine, Lilly and UCB.
Accreditation Statement: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Learning Objectives: At the conclusion of this activity, the participant will have increased competence related to:
• Discussing the pathophysiology of Psoriasis (PsO) and Psoriatic Arthritis (PsA), including the identification of targets for therapy
• Recognizing the clinical characteristics of PsO, PsA and associated comorbidities • Applying guideline-based criteria for the diagnosis and assessment of PsO and PsA
• Selecting appropriate therapies to treat and manage moderate to severe PsO based on current evidence for efficacy, safety, and adherence
• Classifying the spectrum of comorbidities associated with PsO and PsA
• Determining treatment plans aimed at minimizing the impact of associated comorbidities on health outcomes and quality of life
Other Comments: Dinner will be served at this event.
Register Online
Speakers: Tomas Chao, PA-C - Atlanta North Dermatology Lakshi Aldredge, ANP, MSN, ANP-BC, DCNP - VA Hospital
Credit Designation: The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Psoriasis Foundation designates this live activity for a maximum of 2 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity is supported by independent educational grants from Johnson and Johnson Innovative Medicine, Lilly and UCB.
Accreditation Statement: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Learning Objectives: At the conclusion of this activity, the participant will have increased competence related to:
• Discussing the pathophysiology of Psoriasis (PsO) and Psoriatic Arthritis (PsA), including the identification of targets for therapy
• Recognizing the clinical characteristics of PsO, PsA and associated comorbidities • Applying guideline-based criteria for the diagnosis and assessment of PsO and PsA
• Selecting appropriate therapies to treat and manage moderate to severe PsO based on current evidence for efficacy, safety, and adherence
• Classifying the spectrum of comorbidities associated with PsO and PsA
• Determining treatment plans aimed at minimizing the impact of associated comorbidities on health outcomes and quality of life
Other Comments: Dinner will be served at this event.